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infected PBMC to adhere to endothelial cells and therefore
decrease the probability of infection due to the absence of viral
transfer between EHV-4-infected PBMC and endothelial cells. We
were able to show that the EHV-4 UL56 in comparison to its
counterpart in EHV-1 was able to downregulate VLA-4 on equine
dermal cells. Taken together, we conclude that systemic spread and
higher pathogenic potential of EHV-1 compared to EHV-4 is caused
by differences in their abilities to infect and/or reprogram mono-
nuclear cells with respect to virus transfer to endothelial cells.
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Equine herpesvirus type 1 (EHV-1) continues to cause severe
outbreaks of abortions and myeloencephalopathy in horses
despite widely used vaccination. The aim of this work was to
determine the effects of frequent vaccination with an inactivated
EHV vaccine on immune development in horses. Fifteen EHV-1
naïve mares were vaccinated a total of 5 times over a period of 8
months with intervals of 20, 60, 90 and 60 days between vaccine
administrations. Total antibody and antibody isotype responses
were evaluated with a new sensitive EHV-1 Multiplex assay to
glycoprotein C (gC) and gD for up to 14 months after initial
vaccination. Antibodies peaked after the ﬁrst two vaccine doses
and then declined despite a third administration of the vaccine.
The fourth vaccine dose was given at 6 months and the gC and gD
antibody titers increased again. Mixed responses with increasing
gC but decreasing gD antibody values were observed after the
ﬁfth vaccination at 8 months. IgG4/7 isotype responses mimicked
the total Ig antibody production to vaccination most closely.
Vaccination also induced short-lasting IgG1 antibodies to gC, but
not to gD. EHV-1-speciﬁc cellular immunity induced by vaccina-
tion developed slower than antibodies, was dominated by IFN-g
producing T-helper 1 (Th1) cells, and was signiﬁcantly increased
compared to pre-vaccination values after administration of 3
vaccine doses. Decreased IFN-g production and reduced Th1-cell
induction were also observed after the second and fourth vacci-
nation. Overall, repeated EHV vaccine administration did not al-
ways result in increasing immunity. The adverse effects on
antibody and cellular immunity that were observed here when
the EHV vaccine was given in short intervals might in part explain
why EHV-1 outbreaks are observed despite widely used vacci-
nation. The ﬁndings warrant further evaluation of immune re-
sponses to EHV vaccines to optimize vaccination protocols for
different vaccines and horse groups at risk.
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Equine herpesvirus-1 (EHV-1) is one of the major viral pathogens
of equids causing respiratory disease, abortion and neurologicdisease. Recently, there have been increasing incidences of
neurologic disease caused by EHV-1 in many countries. Type-I
interferon (IFN) is considered to be the ﬁrst line of defense against
many viral pathogens. It has been reported earlier that EHV-1
infects the endothelial cells lining the blood vessels of the central
nervous system and induces vasculitis leading to neurologic signs
in horses. We have previously shown that the neuropathogenic
T953 strain of EHV-1 suppresses type-I IFN in equine endothelial
cells (EECs) (Sarkar et al., 2015). However, the antiviral effect of
type-I IFN in the endothelial cells has not been studied in detail.
We hypothesized that EHV-1 infection inhibits type-I IFN-
mediated antiviral response. In this study we investigated the
antiviral effect of type-I IFN against the neuropathogenic T953
strain of EHV-1 in vitro in EECs. To study the effect of type-I IFN,
sub-conﬂuent monolayers of EECs were stimulated with puriﬁed
recombinant equine IFN-a (rEqIFN-a) for 24 h before infecting
with T953 strain of EHV-1 or vesicular stomatitis virus expressing
green ﬂuorescent protein (VSV-GFP) at an MOI¼0.1. VSV-GFP was
used as a positive control for IFN-sensitive virus. At different
times post infection (pi), cell supernatants were collected and
titrated by plaque assay on rabbit kidney-13 cells to determine
the number of virus particles. In a separate experiment, rEqIFN-a-
treated EECs were resuspended into single cell suspensions and
an infectious center assay was performed to determine if rEqIFN-
a interfered with the infectivity of the IFN-treated cells. The re-
sults from both of the experiments demonstrated that T953 strain
of EHV-1 was partially resistant to the antiviral effect of exoge-
nously supplied rEqIFN-a. To investigate the mechanism of
resistance, the effects of EHV-1 infection on JAK-STAT signaling
pathways were analyzed. Conﬂuent monolayers of EECs were
infected with T953 strain of EHV-1 at an MOI of 5.0 and at
different times pi (3 h and 12 h), cells were stimulated with
rEqIFN-a 30 min prior to lysis for Western blotting analysis to
determine the level of endogenous as well as phosphorylated
STAT-1. Mock infected EECs stimulated with rEqIFN-a or MEM
were used as either positive or negative controls, respectively. The
results demonstrated that the virus infection not only interfered
with STAT-1 phosphorylation, but also suppressed exogenous
rEqIFN-a-induced STAT-1 phosphorylation. The ﬁndings were
further conﬁrmed by indirect immunoﬂuorescence assay which
showed that EHV-1 T953 strain prevented rEqIFN-a-induced
nuclear translocation of STAT-1 from cytoplasm. Furthermore,
this study also revealed that downstream of the JAK-STAT
signaling, EHV-1 infection inhibited expression of cellular anti-
viral proteins including IFN-stimulated gene 56 (ISG56) and
viperin. Altogether these data show that the neuropathogenic
T953 strain of EHV-1 evades the host innate immune response by
inhibiting the type-I IFN signaling pathway in EECs.
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Efﬁcacy of antivirals expressed as percentage of inhibition
ACV GCV HPMPC
Reduction of EHV3 production
after 48h
>88% >87% >58%
Reduction of plaque size 84-100% 84-92% 76-85%
Reduction of plaque number 76-96% 58-93% 13-47%
10th IEIDC Abstracts / Journal of Equine Veterinary Science 39 (2016) S66eS71S68EHV-1 vaccination is performed to ameliorate clinical respiratory
disease, late term abortion and myelopathy. Inactivated virus
vaccines and few modiﬁed-live virus vaccines are available. A
product in Europe claiming to aid in abortion prevention has
a high antigenic load and manufacturer-speciﬁc adjuvants
(Equip®EHV-1,4; Zoetis). While few horses develop local swelling
or fever after IM administration, this is likely unacceptable for
horse owners, and could lead to decreased compliance with
vaccination. However, a post-vaccination systemic inﬂammatory
response (SIR) could also indicate a more robust speciﬁc immu-
nity. Therefore, we hypothesised that horses with detectable SIR
will have higher virus-neutralising (VN) antibody titres than
horses without detectable SIR.We also tested whether differences
exist between vaccinated mules and horses. Adult mules (n¼11)
and horses (n¼11), previously vaccinated with an inactivated
EHV-1/EHV-4 vaccine (Equip®EHV-1,4) at 6-month intervals on at
least two occasions were used. Booster vaccination was per-
formed on day 0 (d0) of the study. Before and daily post vacci-
nation for 7 days, rectal temperature, nasal discharge and
mandibular lymph node (MLN) size were recorded. Blood was
collected prior to vaccination (d0), on days 3, 5, 7, 14, 21, and
additionally when fever was detected. Serum amyloid A (SAA)
was measured on d0 e d7 as a marker of SIR. VN titres were
measured on d0, 7, 14 and 21. Normality was assessed with the
Shapiro-Wilk-test. Mann-Whitney-test was applied to compare
horses tomules. A Spearman-correlation-coefﬁcient (R2) between
the maximum increase in VN titres and the highest SAA value was
calculated. Signiﬁcance was pre-set at p<0.05. Pre-vaccination
clinical examswere all normal. A single episode of fever (>38.0C)
occurred in 4/11 (36%) horses and 2/11 (18%) mules (total fever
days per subject ¼ 1). All subjects showed seromucous nasal
discharge for 7 days. MLN were unremarkable throughout the
study. All subjects had increased post-vaccination SAA concen-
tration (>1.7mg/L) on at least one occasion. VN results (median
[interquartile range]) were signiﬁcantly different (P¼0.0058) be-
tween horses (1:256 [1:64; 1;256]) and mules (1:512 [1:256;
1:512]) on day 7. A statistically signiﬁcant (P<0.05) change in
antibody titres compared to baseline (d0) was observed in mules
on d7. No signiﬁcant difference in SAA between horses and mules
was recorded. A signiﬁcant increase in SAA was observed on d3
(P<0.001) and d5 (P<0.01) compared to d0 in both groups. No
correlation was observed between peak SAA and the increase in
VN titres in horses (R2¼0.09, CI:-0.58-0.65; P¼0.80) or mules
(R2¼0.06, CI:-0.55-0.67; P¼0.86). In conclusion, vaccination
induced SIR characterised by signiﬁcantly increased SAA, but the
intensity of SIR was not associated with a higher VN antibody
response. The immune response differed between groups, with
higher antibody production in mules. Overall, the absence of a
signiﬁcant post-vaccination rise in VN titres suggests that the
adequacy of current vaccination programs should be further in-
vestigated.
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Liege, BelgiumEquine Coital Exanthema (ECE) is an infectious, venereally
transmittedmucocutaneous disease of mares and stallions caused
by equid herpesvirus 3 (EHV3). Prevention in stallions is based on
segregating affected mares from reproduction. However, reac-
tivated virus from latently infected mares is re-excreted subclin-
ically, and therefore the prevention approach previously
described does not eliminate the risk of contagion. Outbreaks of
ECE have a negative impact on horse reproductive practices; there
is thus an urgent need of a speciﬁc method of treatment and
prevention. In previous studies, we demonstrated the efﬁcacy of
antiviral compounds, such as acyclovir (ACV), ganciclovir (GCV)
and cidofovir (HPMPC), against EHV3 reference strain. The aim of
the present work was to evaluate these compounds against
different ﬁeld isolates of EHV3 in vitro. Six EHV3 isolates were
obtained from affected mares in Argentina from 2007 and 2008.
They were selected according to phenotypic and genetic differ-
ences determined prior to this study in order to form a group of
viruses representative of the variety of the circulating EHV3.
Monolayers of EDerm cells in 12- wells tissue culture plates were
infected with 30 plaque forming units/well of each ﬁeld strain.
After two h. of incubation, overlay medium, with and without
carboxymethyl cellulose (CMC) 0.75%, supplemented with ACV 5
mg/ml, GCV 0.05 mg/ml and HPMPC 2 mg/ml was added. The two
sets of plaques were incubated at 37C in a CO2 incubator for 72 h.
The same experiment with each viral isolate but without the
addition of antiviral compound was performed as control. To
quantify EHV3 production, aliquots of the supernatant (without
CMC) were taken at 48 and 72 h after infection, and DNA was
extracted and analyzed by a quantitative real time PCR (qPCR)
targeting the gG gene. To determine plaque size and plaque
number, the cells with CMC 0.75% were ﬁxed and stained after 72
h with 0.1% formalin-buffered crystal violet solution. Results
shown in the following table are the mean value of the three
independent experiments.
In conclusion, the susceptibility of EHV3 ﬁeld isolates to ACV, GCV
and HPMPC was similar among them, and the results are in
concordance with the ones obtained with the reference EHV3
strain. The antiviral effect of these compounds was similar for
plaque size, but for plaque number and EHV3 production, HPMPC
was the least effective, being ACV and GCV similar regarding their
effectiveness against EHV3. However, as GCV was the most efﬁ-
cient compound, it will be considered to be evaluated topically on
experimentally infected mares.
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Equine herpesviruses (EHVs) are common respiratory pathogens
in horses and other equids, which are responsible for serious
health, welfare and ﬁnancial consequences worldwide. The
